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Objective To evaluate whether premature infants who received an exclusive human milk (HM)-based diet and a
HM-derived cream supplement (cream) would have weight gain (g/kg/d) at least as good as infants receiving a stan-
dard feeding regimen (control).
Study design In a prospective noninferiority, randomized, unmasked study, infants with a birth weight 750-1250 g
were randomly assigned to the control or cream group. The control group received mother’s own milk or donor HM
with donor HM-derived fortifier. The cream group received a HM-derived cream supplement if the energy density of
the HM tested <20 kcal/oz using a near infrared HM analyzer. Infants were continued on the protocol until 36 weeks
postmenstrual age. Primary outcomes included growth velocities and amount of donor HM-derived fortifier used.
The hypothesis of noninferiority was established if the lower bound of the one-sided 95% CI for the difference in
weight velocities exceeded 3 g/kg/day.
Results There were no differences between groups in baseline demographics for the 78 infants studied except
racial distribution (P = .02). The cream group (n = 39) had superior weight (14.0  2.5 vs 12.4  3.0 g/kg/d,
P = .03) and length (1.03  0.33 vs 0.83  0.41 cm/wk, P = .02) velocity compared with the control group
(n = 39). There were no significant differences in amount of fortifier used between study groups. The 1-sided
95% lower bound of the CI for the difference in mean velocity (cream-control) was 0.38 g/kg/d.
Conclusions Premature infants who received HM-derived cream to fortified HM had improved weight and length
velocity compared with the control group. HM-derived cream should be considered an adjunctive supplement to an
exclusive HM-based diet to improve growth rates in premature infants. (J Pediatr 2014;165:915-20).
H
uman milk (HM) feeding is associated with substantial benefits to the health and development of infants, especially
premature infants.1 The American Academy of Pediatrics recommends that all preterm infants receive HM including
donor HM if mother’s own milk is unavailable.2 Recently, the use of an exclusive HM-based diet for very low birth
weight (BW) infants has significantly risen. Sullivan et al found that an exclusive HM-based diet in infants#1250 g BW reduced
the rate of necrotizing enterocolitis (NEC) by 50% and surgical NEC by 90%3 In this same study, there was no difference in
growth between infants receiving an exclusive HM-based diet compared with infants receiving bovine milk fortifier.3
A large cohort study of infants <1000 g BW showed that growth velocities greater than current guidelines of 15 g/kg/d are
needed to ensure that infants maintain their BW percentile on the growth curve and avoid extrauterine growth restriction.4 OneFrom the 1US Department of Agriculture (USDA)/
Agricultural Research Service (ARS), Children’s Nutrition
Research Center, Section of Neonatology, Department
of Pediatrics, Baylor College of Medicine, Texas
Children’s Hospital, Houston, TX; 2Department of
Pediatrics, University of Texas Health Science Center,
San Antonio, TX; and 3Prolacta Bioscience, Industry, CA
Funded by the US Department of Agriculture (USDA)/
Agricultural Research Service (ARS) (58-6250-6-001) and
National Center for Research Resources General Clinical
Research for Children (RR00188). Prolacta Bioscience
provided the product for the study and assisted in data
analysis. Contents of this publication do not necessarily
reflect the views or policies of the USDA, nor doesstudy evaluating macronutrient composition of mother’s milk and donor HM
found high variability in fat, protein, and energy content.5 Another study evalu-
ating the energy content of donor HM found that on average, donor milk was
19 kcal/oz but 25% of the samples had caloric values <17.3 kcal/oz, which is
significantly lower than the 20 kcal/oz or more reported in mother’s milk.6
A novel pasteurized donor HM-derived cream supplement is now available. It
can be added to an infant’s diet to help improve overall caloric intake without
substantially altering the total feeding volume given to the infant. We hypothe-
sized that premature infants who received an exclusive HM-based diet and a
HM-derived cream supplement (cream) would have weight gain (g/kg/d) at least
as good as infants receiving a standard feeding regimen (control).mention of trade names, commercial products, or orga-
nizations imply endorsement by the US government. A.H.
and C.B. received financial support and receive speaker
honoraria from Prolacta Bioscience. M.L. and D.R. are
employees of Prolacta Bioscience. The other authors
declare no conflicts of interest.
Registered with ClinicalTrials.gov: NCT01487928.
Copyright ª 2014 The Authors. Published by Elsevier Inc. This is an









THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 165, No. 5Methods
Using a prospective randomized study design, preterm in-
fants 750 to 1250 g BW receiving an exclusive HM-based
diet were identified after admission to the Neonatal Intensive
Care Unit of the 2 study centers, Texas Children’s Hospital
(Houston, Texas) or University Health System at San Anto-
nio (San Antonio, Texas). Inclusion criteria were 750-1250 g
BW, reasonable expectation of survival for study duration
through 36 weeks postmenstrual age (PMA) or weaned
from fortification (whichever comes first), adherence to a
feeding protocol providing an exclusive HM-based diet and
potentially a donor HM-derived cream supplement, achieve-
ment of enteral feeds by 21 days of life, and informed consent
from parent or legal guardian. Infants were excluded that had
major congenital anomalies or clinically significant congen-
ital heart disease, low expectation for survival, high potential
for early transfer to a nonstudy institution, enrollment in
another clinical study that affected nutritional management,
failure to start minimum enteral feeds before 21 days of life,
presence of intestinal perforation or stage 2 NEC by modified
Bell Criteria7 prior to tolerating fortified feeds, or inability to
participate in the study for any reason based on the decision
of the study investigator.
This study was approved by the Institutional Review Board
of Baylor College of Medicine and Affiliated Hospitals and
The University of Texas Health Science Center at San Anto-
nio. Infants meeting inclusion criteria were identified, and
their parents approached for consent until 21 days of age as
infants needed to have started enteral feeds by this time
and prior to initiation of fortification. After informed written
parental consent was obtained, infants were randomized into
1 of 2 groups via blocks of 4, the size of which was blinded
(cream or control group). Because of the nature of the inter-
ventions by which the nutrition was prepared and delivered,
masking of the study groups was not possible at 1 site. The
cream supplement mixes readily with HM and its addition
does not change the composition or consistency of the
HM. At 1 site, we were unable to prepare the milk and deliver
it to the infant in a blinded fashion for logistical reasons.
The sample size was determined based on the primary
endpoint of the rate of weight gain from initiation of enteral
feeds to 36 weeks PMA. Based on available data evaluating an
exclusive HM-based diet, the SD of weight gain was 4 g/kg/d.3
For this determination, we hypothesized that we would iden-
tify a lack of inferiority (defined as a difference of weight gain
of less than 3 g/kg/day, ie, a lower bound of 3) in the mean
weight gain for the cream group compared with the control
group. With a 1-sided 5% significance level and 90% power,
a sample size of 62 (n = 31 per group) was needed to demon-
strate a difference of this magnitude between the 2 study
groups. However, it was anticipated that some infants might
not require cream supplement in the intervention group
because their HM was $20 kcal/oz. To account for this, the
sample size was increased by 25% to 78 (n = 39 per group).
The cream group was defined as the intent to treat group916although some infants in this group might not have received
cream supplement.
Infants were fed an exclusive HM-based diet according to
the investigative site’s standard of care. Infants received
mother’s own milk supplemented with pasteurized donor
HM when mother’s milk was unavailable. Donor HM was
from 2 sources (Texas Children’s Hospital received donor
HM from Prolacta Bioscience, Industry, California and Uni-
versity Health System at San Antonio received donor HM
from a member milk bank of the Human Milk Banking
Association of North America). Both study sites followed
protocols and standards specific to milk collection, transpor-
tation, storage, preparation, and fortification. The standard
feeding regimen provided each group HM fortified with
pasteurized donor HM-derived fortifier, Prolact+H2MF
(Prolacta Bioscience, Industry, California8). Fortification
began by the time infants were tolerating 100 mL/kg/d of
enteral feeds if not sooner. Once fortified feeds were toler-
ated, the caloric content of HM was determined daily from
a 24-hour batch sample using a commercially available near
infrared milk analyzer (Spectrastar 2400RTW; Unity Scienti-
fic, Brookfield, Connecticut). This caloric information was
only available to study investigators and was not part of
routine care at either study site. For the control group, infants
received the standard feeding regimen (without cream sup-
plement) and caloric information was recorded for study
purposes. The cream group received the same standard
feeding regimen with the addition of a donor HM-derived
cream supplement if the HM they were receiving was found
to be <20 kcal/oz after analysis. The donor HM-derived
cream supplement, Prolact CR, (Prolacta Bioscience8) is
standardized to 25% lipids and contains 2.5 kcal/mL. The
appropriate amount of cream was added to HM to bring
the caloric content to approximately 20 kcal/oz. Donor
HM or own mother’s milk was adjusted with cream supple-
ment to a target level of 20 kcal/oz because it is generally
assumed that mother’s milk is 20 kcal/oz. The control group
received fortification based on the assumption that the HM
was 20 kcal/oz.
Infants were followed for study duration from initiation of
enteral feeds until 36 weeks PMA or weaned from fortifier
(whichever occurred first), transferred to a nonstudy institu-
tion, removed from the study, or death. Weight was recorded
daily. Recumbent length and head circumference (HC) were
measured weekly using a length board and tape measure,
respectively. Primary outcomes included growth velocity
(weight, length, and HC) and the amount of donor HM-
derived fortifier used. The incidence of sepsis, NEC, or death
was recorded. Weight gain velocity (g/kg/d) was calculated
using the Patel Method.9
All quantitative data, including the growth variables and
volumes of nutrition, were summarized by the use of descrip-
tive statistics (mean  SD and median  IQR). Qualitative
data were summarized using proportions and percentages.
The primary analytical approach to the study endpoint of










November 2014 ORIGINAL ARTICLESfeeding to 36 weeks PMA or weaned from fortifier employed
an intent-to-treat paradigm. The intent-to-treat population
for this study was defined as all randomized subjects who
received any enteral nutrition. If a study subject failed to
complete the requisite study period (through 36 weeks
PMA or weaned from fortifier), then the rate of change in
weight was calculated for the time on study. The comparison
between the study arms with respect to the primary endpoint
was made by the use of a 1-sided 95% CI for the difference in
rate of weight change over the study period. Groups were
compared using the 2-sample t test, c2 test, and Fisher exact
test. Statistical significance was defined as P < .05. Statistical
analyses were performed using NCSS 9 software-2013
(NCSS, LLC, Kaysville, Utah).
Results
We enrolled 78 infants (Figure). There were no significant
differences in infant demographics and characteristics at
the time of study enrollment except racial distribution
(Table I). For study duration, infants in the cream group
had greater weight and length velocity as well as greater
weight and length velocity from the time they regained BW
compared with the control group (Table II). There was noFigure. CONSORT diagram.
Randomized Trial of Human Milk Cream as a Supplement to Sta
Diet in Infants 750-1250 g Birth Weightsignificant difference in HC growth (Table II). The 1-sided
95% lower bound of the CI for the difference in mean
velocity (cream-control) was 0.38 g/kg/d, which was above
the value of 3 determined as the lower bound for lack of
inferiority. There were no significant differences in the
amount of fortifier used between the groups. There were
no cases of NEC and no deaths among study infants in
either group (Table III). The number of sepsis episodes
were not significantly different between the 2 groups
(Table III). None of the infants in the cream group had the
intervention discontinued because of intolerance or other
adverse outcomes. 33 of the 39 infants (85%) that were
assigned to the cream group received the cream
supplement including all 11 infants assigned to the cream
group at the San Antonio study site. The mean (SD) daily
amount of cream supplement given to infants requiring
cream was 5.1  2.4 mL (median = 4.8 mL). The amount
of cream supplement given to infants requiring cream
varied day to day as the 24-hour batch of HM was sampled
for caloric analysis each day.
Caloric content (kcal/oz) of mother’s ownmilk (21.2 5.6
vs 18.8  5.6, P < .01) and donor HM (21.8  1.5 vs
20.2  2.1, P < .01) differed between study sites with higher
caloric content at Texas Children’s Hospital. We found andard Fortification of an Exclusive Human Milk-Based 917




n = 39 P value
BW, g 972  150* 969  140 .92
Gestational age, wk 27.7  2.1 27.6  1.6 .88
Sex, % male 54 49 .65
Race, %,
Hispanic/White/Black/other
51, 23, 21, 5 20, 26, 46, 8 .02
Apgar at 5 min 7  2† 7  4† .43
Mechanical ventilation, % 21 18 .77
Antenatal steroids, % 80 80 1.0
*Mean  SD.
†Median (IQR).
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 165, No. 51.2 kcal/oz difference in caloric content when comparing the
milk analyzer results with primary AOAC International lab-
oratory methods. Adjusting the caloric content of the milk to
reflect the true kcal/oz gives the caloric content of mother’s
own milk at each center (20 vs 17.6 kcal/oz) and donor
HM (20.6 vs 19 kcal/oz), respectively.
Discussion
We found that adding a unique HM-derived cream product
significantly enhanced the growth of very preterm infants.
This study evaluated an entirely HM-based approach to
nutrition in this group of infants that includes the use of a
human derived fat supplement.
HM feeding, appropriately fortified, is the recommended
nutritional source for all preterm infants.2 Studies have shown
than an exclusive HM-based diet decreases the incidence of
NEC and parenteral nutrition days.3,10 A pasteurized donor
HM-derived cream supplement is a source of fat calories to in-
crease the caloric density of aHM-based diet without a substan-
tial increase in the volume of feeds or using non-HM based
nutritional products. Recent studies have reported that the
caloric content of mother’s milk and donor HM is often
<20 kcal/oz, and fat content is the most variable compo-
nent.5,6,11 In this study, for infants in the intervention group,
if the caloric content of the milk they were receiving was
<20 kcal/oz, then donor HM-derived cream supplement was
added to increase the calories to 20 kcal/oz. Infants received
the supplement starting at 100 mL/kg/d of fortified feeds while
they were advancing to full enteral volume. It has become
evident from recent reports that early nutrition improvesTable II. Comparison of growth velocities
Control gro
Weight velocity (g/kg/d) 12.4 
Length velocity (cm/wk) 0.83 
HC (cm/wk) 0.84 
Weight velocity from time infant regained BW (g/d) 18.6 
Weight velocity from time infant regained BW (g/kg/d) 13.7 
Length velocity from birth (cm/wk) 0.76 
HC from birth (cm/wk) 0.62 
*Mean  SD.
918growth, decreases postnatal growth failure, and improves out-
comes.12-14 Appropriate growth of preterm infants is crucial
to improved outcomes. For example, Ehrenkranz et al reported
that as the rate of weight gain and HC increased in extremely
lowBW infants, the incidence of cerebral palsy and poor neuro-
developmental scores decreased significantly at 18-22 months’
corrected age.14
Very low BW infants may benefit from individualized
fortification of their enteral nutrition because of the vari-
ability of the macronutrient composition of HM.5 The donor
HM-derived fortifier provides and often exceeds (depending
on the amount given) the recommended amounts of protein
(g/kg/d) for premature infants.15,16 As fat concentration
varies between HM samples and may be low in some cases,
infants may benefit from extra fat in addition to fortifiers.
However, published data are limited in this regard. A Co-
chrane review evaluated fat supplementation of HM for pro-
moting growth in preterm infants and found that there was
insufficient evidence to make recommendations for prac-
tice.17 Polberger and others conducted a double-blind ran-
domized study of 28 infants fed HM fortified with HM
protein and/or HM fat.18 For the 14 infants that received
HM fat, there was no difference in short term growth.18
HM was analyzed for macronutrient composition in this
study but there was not a description of the amount or the
method of how HM fat was supplemented to the feeds.
Results from our study show that infants who receivedHM
fat had improved short-term growth in weight and length.
Although we did not perform body composition studies on
these infants, the increase in length velocity in addition to
weight gain suggests that infants had gains in lean body
mass.15 Preterm infants require a high protein to energy ratio
to achieve catch up growth without fat accretion and that
growth should focus on length gain and lean body mass.15 In-
fants only received donor HM-derived cream supplement
when the HM calories were <20 kcal/oz to raise the calories
to 20 kcal/oz, which is the caloric content reported for
mature HM.15,16
Other strategies aimed at increasing the amount of fat cal-
ories in enteral nutrition include adding medium-chain tri-
glycerides because of potential for high absorption by
premature infants. Although this has been used in clinical
practice, there is only 1 small study evaluating this supple-
mentation approach. That study did not show an effect on
growth when medium-chain triglycerides were added toup, n = 39 Cream group, n = 39 P value
3.9* 14.0  2.5 .03
0.41 1.03  0.33 .02
0.22 0.90  0.19 .21
6.4 21.8  5.4 .02
4.0 15.7  2.5 .02
0.29 0.95  0.34 .01
0.21 0.64  0.19 .58
Hair et al
Table III. Clinical outcomes of study infants
Control group, n = 39 Cream group, n = 39 P value
NEC (%) 0 0 -
Sepsis (%) 7.7 10.3 1.0
Death (%) 0 0 -
November 2014 ORIGINAL ARTICLESHM.19 In addition, there are concerns that premature infants
have feeding intolerance associated with the addition of oils
to HM feeds and that medium-chain triglycerides as used
in this setting are not a sterile product. A benefit of the donor
HM-derived cream supplement is that it is made from
pasteurized donor HM and mixes readily and fully with
HM. The addition of HM cream was well tolerated by the in-
fants in this study. We selected infants with a BW between
750 and 1250 g as this population is less likely to have feeding
intolerance frequently observed in infants with a BW <750 g.
Further studies would be needed in infants <750 g BW to
evaluate its use in that group of infants.
A limitation of this study was that the near-infrared milk
analyzer used was a secondary method for the measurement
of HM and after comparison with primary AOAC methods,
despite calibration to bias samples, we found that there was a
1.2 kcal/oz overestimation of the caloric content of the HM
samples. Although there is some variation with any method
used, the benefit of the milk analyzer used in this study is
that it requires a small volume sample and provides results
quickly, which is ideal in a clinical setting. There were 2 sour-
ces of donor HM used in the study and after correcting for
the overestimation, donor HM was higher in mean calories
(20.6  1.5 kcal/oz) at Texas Children’s Hospital compared
with 19.0  2.1 kcal/oz at the other site.
The reason for the discrepancy in caloric content between the
milk supplied by the 2 banks is 2-fold.Wojcik et al reported that
the average caloric value of milk received from a nationwide
sample of donors to a commercial milk bank was 19.2 kcal/
oz.6 This corresponds to the caloric content of the donor HM
from 1 of themilk banks. The othermilk bank (Prolacta Biosci-
ence) formulates its donor HM through the use of very large
donor pools and specific processing steps to ensure it contains
a minimum of 20 kcal/oz as determined by AOAC primary
methodologies. These practices are not currently implemented
by any other North American milk bank.
Donor HM has been reported to be lower in protein, fat,
and caloric content than mother’s own milk and differ
from the values reported in the literature for mature
HM.5,6 However, mother’s milk and donor HM were similar
in mean calories and measured above 20 kcal/oz at Texas
Children’s Hospital. Therefore, more infants may have qual-
ified for cream supplementation than received it because of
the overestimation of calories and the high caloric content
of mother’s milk and donor HM used in the study. Despite
this, infants in the cream group had better weight and length
gain compared with the control group.
In conclusion, premature infants who received HM-
derived cream supplement to an exclusive HM-based dietRandomized Trial of Human Milk Cream as a Supplement to Sta
Diet in Infants 750-1250 g Birth Weighthad superior weight and length velocity compared with in-
fants who did not receive the supplement. As poor postnatal
growth remains a major challenge in neonatology, HM-
derived cream supplement should be considered in infants
with slow growth or evidence that the HM they are receiving
is low in fat content. n
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This study reviewed autopsy records from The Johns Hopkins Hospital from 1927-1959. The analysis was restrictedto infants who died within 30 days after birth from a congenital heart defect. A total of 170 autopsies were
described.
The 4 most frequent cardiac malformations encountered were ventricle septal defects (18%), transposition of the
great vessels (16%), coarctation of the aorta (14.8%), andmitral and/or aortic atresia (11.5%). The next most frequent
malformations were patent ductus arteriosus, pulmonary stenosis or atresia with intact ventricular septum, tetralogy
of Fallot, truncus arteriosus, the origin of both great vessels from the right ventricle, and cor triloculare. These 10 le-
sions were found in 151 (88% percent) of the 170 cases.
Most infants with a ventricular septal defect died from prematurity, infection, or a serious associated noncardiac
malformation leading the authors to suggest that the development of better care for premature infants would allow
these infants to survive the neonatal period. As these improvements evolved, these infants survived early on but
they still faced congestive heart failure or pulmonary hypertension in infancy.
Infants with transposition of the great vessels usually died within the first 7 days of life, and their cardiac issue was
the primary cause of death. Unlike the other major defects, infants with a coarctation of the aorta lived several days
until the patent ductus closed. The majority of these infants had no other malformations. The infants with atresia of
either the aortic or mitral valve died within a few days of life, and most had no other issues.
Medical and surgical treatments were not effective for most of neonates described in this paper. Dr Helen Taussig, a
coauthor of this article, would be a key developer of the Blalock-Taussig shunt. This revolutionary palliative procedure
prolonged the lives of many patients with severe congenital heart defects as they awaited corrective surgery. Prosta-
glandin E1 would not be available for several more years. The advances in congenital heart surgery were just being
developed but would not be available for several years after this study was published. The neonatal mortality rate
for the lesions mentioned in this study is close to 0 in 2014 thanks to these and many more advances in the medical
and surgical management of these neonates.
Reginald L. Washington, MD
Rocky Mountain Hospital for Children
Denver, Colorado
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